Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 11, 2012
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) determined that Eisai has met the FDA's Written Request requirements...
-
Dec 7, 2012
Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer...
-
Nov 30, 2012
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA)...
-
Nov 28, 2012
Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast...
-
Nov 26, 2012
Following a productive first year of headcount growth and scientific advancement, H3 Biomedicine Inc. (H3), a biopharmaceutical company specializing...
-
Nov 19, 2012
In conjunction with Eisai Co., Ltd., the Eisai USA Foundation, the charitable arm of Eisai Inc., announced today that it will be making a...
-
Nov 12, 2012
Morphotek(® )Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug...
-
Nov 8, 2012Eisai Recognizes Inaugural LGS Awareness Day and Epilepsy Awareness Month with Launch of New Caregiver Support Video
With approximately two million people in the United States living with epilepsy, including a severe and rare form called Lennox-Gastaut syndrome...
-
Oct 22, 2012-- FYCOMPA is the First FDA-Approved Non-competitive AMPA Glutamate Receptor Antagonist --
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA (perampanel) as an adjunctive treatment for...
-
Oct 4, 2012H3 Biomedicine is first partner for program aimed at generating 'first-in-class' patient-relevant targets based on synthetic lethality screens
Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines,...